Efficacy of fetal hemoglobin inducers in adult transfusion-dependent beta-thalassemia patients: a systematic review and meta-analysis
DOI:
https://doi.org/10.13181/mji.oa.257796Keywords:
beta-thalassemia major, blood transfusion, safety, treatment outcomeAbstract
BACKGROUND Patients with transfusion-dependent beta-thalassemia (TDBT) face risks of iron overload, which also burdens national expenditures in Indonesia. Elevated fetal hemoglobin (HbF) expression is associated with reduced blood transfusion dependency. This study aimed to assess the efficacy and safety profile of HbF inducers as adjuvant therapy for adult patients with TDBT and appraise its feasibility for Indonesian patients.
METHODS This study analyzed 7 trials of HbF inducers, such as hydroxyurea, thalidomide, butyrate, and decitabine, in 382 adult participants (mean age >16), including 28 patients with non-TDBT. Outcomes assessed included hemoglobin (Hb) levels, transfusion needs, and adverse events (AEs). Studies were sourced from PubMed, Cochrane, Embase, and individual searches. The standardized mean difference (SMD) was used as the primary effect size. The protocol was registered in PROSPERO (CRD4202454646368).
RESULTS High heterogeneity was observed, with HbF inducers associated with a significant decrease in transfusion needs (SMD = −0.88; 95% confidence interval [CI] = −1.37 to −0.26); I2 = 79%, P✗2<0.01). No significant change in Hb levels was found (SMD = 0.11; 95% CI = −0.69 to 0.91; I2 = 90%, P✗2<0.01). The most common AEs were transaminitis and cytopenias, which were tolerable and alleviated upon dose cessation.
CONCLUSIONS HbF induction agents can be used as adjuvant therapy for TDBT, considering their cost-effectiveness, efficacy, and safety profiles.
Downloads
References
Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of β-thalassemia. Eur J Haematol. 2020;105(6):692-703. https://doi.org/10.1111/ejh.13512
Wahidiyat PA, Sari TT, Rahmartani LD, Iskandar SD, Pratanata AM, Yapiy I, et al. Thalassemia in Indonesia. Hemoglobin. 2022;46(1):39-44. https://doi.org/10.1080/03630269.2021.2023565
Rujito L, Basalamah M, Siswandari W, Setyono J, Wulandari G, Mulatsih S, et al. Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: a study on β-thalassemia and hemoglobin E/β-thalassemia patients in Indonesia. Hematol Oncol Stem Cell Ther. 2016;9(2):55-63. https://doi.org/10.1016/j.hemonc.2016.02.003
Ministry of Health of the Republic of Indonesia. [Regulation of the Minister of Health of the Republic of Indonesia No. HK.01.07/Menkes/1/2018 on National Guidelines for Medical Services: thalassemia management]. Jakarta: Ministry of Health of the Republic of Indonesia; 2018. Indonesian.
Bou-Fakhredin R, De Franceschi L, Motta I, Cappellini MD, Taher AT. Pharmacological induction of fetal hemoglobin in β-thalassemia and sickle cell disease: an updated perspective. Pharmaceuticals (Basel). 2022;15(6):753. https://doi.org/10.3390/ph15060753
Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations [updated Oct 2013] [Internet]. The GRADE Working Group; 2013 [cited 2024 Oct 1]. Available from: guidelinedevelopment.org/handbook.
Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated Mar 2011] [Internet]. The Cochrane Collaboration; 2011 [cited 2024 Oct 1]. Available from: www.handbook.cochrane.org.
Bhattacharjee U, Khadwal A, Shafiq N, Lad D, Sharma P, Das R, et al. A phase 2 randomized controlled trial of single-agent hydroxyurea versus thalidomide among adult transfusion dependent β thalassemia patients. Indian J Hematol Blood Transfus. 2023;39:266-75. https://doi.org/10.1007/s12288-022-01620-3
Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, et al. A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. Sci Rep. 2022;12(1):2752. https://doi.org/10.1038/s41598-022-06774-8
Kalantri SA, Ray R, Chattopadhyay A, Bhattacharjee S, Biswas A, Bhattacharyya M. Efficacy of decitabine as hemoglobin F inducer in HbE/β-thalassemia. Ann Hematol. 2018;97(9):1689−94. https://doi.org/10.1007/s00277-018-3357-y
Bordbar MR, Silavizadeh S, Haghpanah S, Kamfiroozi R, Bardestani M, Karimi M. Hydroxyurea treatment in transfusion-dependent β-thalassemia patients. Iran Red Crescent Med J. 2014;16(6):e18028. https://doi.org/10.5812/ircmj.18028
de Paula EV, Lima CS, Arruda VR, Alberto FL, Saad ST, Costa FF. Long-term hydroxyurea therapy in beta-thalassaemia patients. Eur J Haematol. 2003;70(3):151−5. https://doi.org/10.1034/j.1600-0609.2003.00037.x
Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica. 2004;89(10):1172−8.
Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995;85(1):43−9. https://doi.org/10.1182/blood.V85.1.43.bloodjournal85143
Jinna S, Khandhar PB. Hydroxyurea toxicity. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2025 [cited 2024 Oct 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537209/.
Keikhaei B, Yousefi H, Bahadoram M. Clinical and haematological effects of hydroxyurea in β-thalassemia intermedia patients. J Clin Diagn Res. 2015;9(10):OM01-3. https://doi.org/10.7860/JCDR/2015/14807.6660
Musiałek MW, Rybaczek D. Hydroxyurea-the good, the bad and the ugly. Genes (Basel). 2021;12(7):1096. https://doi.org/10.3390/genes12071096
National Social Security Council. [JKN statistics book 2015-2019]. Jakarta: National Social Security Council; 2020. Indonesian.
Sari IR. [The effect of hydroxyurea administration on increasing HbF levels in children with transfusion-dependent thalassemia] [master's thesis]. Surabaya: Universitas Airlangga; 2020. Indonesian.
Wulandari RD, Lyrawati D, Fatchiyah F, Fitri LE. Thalassemia major and intermedia patients in East Java do not show fetal hemoglobin level difference in relation to XMNI polymorphism. Med Arch. 2020;74(2):90-4. https://doi.org/10.5455/medarh.2020.74.90-94
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Muhammad Afif Naufal, Ahmad Fauzi, Iris Rengganis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
